CGEN - Compugen Ltd.
| Previous Close | 3.3900 |
| Open | 3.4100 |
| Bid | 3.3700 x 900 |
| Ask | 3.3800 x 900 |
| Day's Range | 3.3500 - 3.4300 |
| 52 Week Range | 2.0000 - 4.3100 |
| Volume | 63,962 |
| Avg. Volume | 123,604 |
| Market Cap | 208.787M |
| Beta (3Y Monthly) | 2.90 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5440 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.00 |
- PR Newswire•4 days ago
Compugen Expands Intellectual Property Portfolio for COM701 with New U.S. Patent Covering Combination Use with anti-PD-1 Antibody
Previously granted U.S. Patent protects combination of COM701 and COM902 HOLON, Israel , July 16, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader ...
- PR Newswire•18 days ago
Compugen Appoints Eran Perry to Its Board of Directors
HOLON, Israel, July 2, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced the appointment of Mr. Eran Perry to its board of directors, effective July 1, 2019. In addition, the Company announced that Yair Aharonowitz, Ph.D. and Arie Ovadia, Ph.D. will retire from its board of directors and will not be brought for re-election at the next annual general meeting. "Eran is an accomplished business leader with over 20 years of experience in the healthcare industry as well as general management, strategy and finance.
- Simply Wall St.•23 days ago
How Many Compugen Ltd. (NASDAQ:CGEN) Shares Do Institutions Own?
A look at the shareholders of Compugen Ltd. (NASDAQ:CGEN) can tell us which group is most powerful. Large companies...
- Simply Wall St.•23 days ago
Do Institutions Own Shares In Compugen Ltd. (NASDAQ:CGEN)?
If you want to know who really controls Compugen Ltd. (NASDAQ:CGEN), then you'll have to look at the makeup of its...
- Zacks•24 days ago
Compugen (CGEN) Upgraded to Strong Buy: Here's What You Should Know
Compugen (CGEN) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Simply Wall St.•last month
The Compugen (NASDAQ:CGEN) Share Price Is Down 63% So Some Shareholders Are Wishing They Sold
It's nice to see the Compugen Ltd. (NASDAQ:CGEN) share price up 18% in a week. But don't envy holders -- looking back...
- PR Newswire•2 months ago
Compugen Presents Update on COM701 Phase 1 Trial at the 2019 ASCO Annual Meeting
HOLON, Israel, June 3, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, was featured in a trial-in-progress poster at the 2019 ASCO Annual Meeting in Chicago, IL. In a poster (Abstract #TPS2657), titled "A phase I study evaluating COM701 in patients with advanced solid tumors," the Company reported that the sixth patient dose cohort of COM701 monotherapy has been completed and that no dose-limiting toxicities were observed in this and prior dose cohorts. The poster is available on Compugen's website at www.cgen.com.
- Zacks•2 months ago
Compugen (CGEN) Upgraded to Buy: Here's What You Should Know
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- PR Newswire•2 months ago
Compugen to Present at the Jefferies 2019 Healthcare Conference
HOLON, Israel , May 22, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that ...
Motley Fool•2 months agoCompugen Ltd. (CGEN) Q1 2019 Earnings Call Transcript
CGEN earnings call for the period ending March 31, 2019.
- Associated Press•2 months ago
Compugen: 1Q Earnings Snapshot
On a per-share basis, the Holon, Israel-based company said it had a loss of 14 cents. The company's shares closed at $3.46. A year ago, they were trading at $3.25. _____ This story was generated by Automated ...
- PR Newswire•2 months ago
Compugen Reports First Quarter 2019 Results
HOLON, Israel , May 20, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today reported financial ...
- PR Newswire•2 months ago
Compugen Doses First Patient in COM701/Opdivo® (Nivolumab) Combination Arm of Phase 1 Study in Patients With Advanced Solid Tumors
HOLON, Israel, May 20, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that it has dosed the first patient in the combination arm of its Phase 1 study, combining escalating doses of COM701 with a fixed dose of Opdivo® (nivolumab) in patients with advanced solid tumors. "Our successful progression through the COM701 monotherapy dose escalation arm, enabled us to initiate the combination study with COM701 and Opdivo," stated Anat Cohen-Dayag, Ph.D., President and CEO of Compugen.
- PR Newswire•2 months ago
Compugen First Quarter 2019 Conference Call Scheduled for Monday, May 20, 2019 at 8:30 AM ET
HOLON, Israel , May 6, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that ...
- Zacks•3 months ago
What Makes Compugen (CGEN) a New Strong Buy Stock
Compugen (CGEN) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- PR Newswire•4 months ago
Compugen Presents Update on COM701 Phase 1 Trial at the 2019 AACR Annual Meeting
HOLON, Israel, April 3, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, was featured in a trial-in-progress poster at The 2019 AACR Annual Meeting in Atlanta, GA. In a poster titled "Phase I study of COM701 (a novel checkpoint inhibitor of PVRIG) in patients with advanced solid tumors", the Company reported that the fifth dose level patient cohort of COM701 monotherapy has been completed and that no dose-limiting toxicities were reported. The poster presented at the meeting is available on Compugen's website.
- PR Newswire•4 months ago
Chinese Regulatory Authority Approves IND Application of Oramed's Oral Insulin Capsules
NEW YORK, March 26, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Chinese partner, Hefei Tianhui Incubator of Technologies Co., Ltd. ("HTIT"), has reached the significant regulatory milestone of approval of an investigational new drug application ("IND") for two doses of its oral insulin (ORMD-0801). The approval of the IND by the Center For Drug Evaluation of the China National Medical Products Administration ("NMPA", formerly the CFDA) of the oral insulin paves the way for the start of clinical trials in China. "We are pleased that the Chinese regulatory authorities have approved the IND, as it sets a clear path forward for approval of oral insulin in China, bringing oral insulin closer to becoming a reality in the Chinese market," stated Oramed CEO Nadav Kidron.
- PR Newswire•4 months ago
Compugen Announces Purchase of Company Shares by its Board of Directors and Members of Management
"My fellow board members and I are excited about Compugen's unique value proposition, its proven computational discovery platform, and differentiated therapeutic pipeline that is designed to address significant unmet needs in immuno-oncology," said Paul Sekhri, Chairman of the Board. "We have the highest confidence in this management team and employees whose talent and dedication made possible the acomplishments of 2018, including the intiation of two clinical trials as well as partnerships with Bristol-Myers Squibb and AstraZeneca.
- PR Newswire•4 months ago
Compugen Announces Issuance of Two U.S. Composition of Matter Patents for COM701, Its Lead Immuno-Oncology Product Candidate
HOLON, Israel, March 12, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that the United States Patent and Trademark Office (USPTO) has granted two composition of matter patents for COM701, the Company's lead immuno-oncology therapeutic antibody candidate. The composition of matter patents expand Compugen's intellectual property protection for COM701 beyond the therapeutic use patent received as part of the Moonshot program in 2017 and cover exclusivity on COM701 in the United States for any purpose.
- Zacks•4 months ago
Achillion (ACHN) Reports Narrower-Than-Expected Loss in Q4
Achillion (ACHN) encourages with narrower-than-expected loss in Q4. However, the company did not generate any revenues in the period.
- Zacks•4 months ago
Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock?
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
- PR Newswire•5 months ago
Compugen to Present at the Cowen and Company 39th Annual Health Care Conference
HOLON, Israel , March 5, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN ), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced ...
- PR Newswire•5 months ago
Compugen Presents Update on COM701 Phase 1 Trial at ASCO-SITC Clinical Immuno-Oncology Symposium
HOLON, Israel, March 1, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, was featured in a trial-in-progress at The ASCO-SITC Clinical Immuno-Oncology Symposium. In poster titled "A Phase 1 Study Evaluating COM701 in Patients With Advanced Solid Tumors," the Company reported that the third single subject dose cohort has been completed with no dose-limiting toxicities (DLTs) reported. "We continue to see significant interest in the study from investigators as they recognize the potential and differentiation of COM701 relative to other checkpoint inhibitors in development," said Henry Adewoye, M.D., Chief Medical Officer at Compugen.
- PR Newswire•5 months ago
Compugen Reports Fourth Quarter and Full Year 2018 Results and Announces Corporate Restructuring to Streamline Operations
Anticipated cost reductions expected to extend cash runway to allow the planned expansion of the ongoing COM701 Phase 1 study Company remains committed to investing in proprietary computational discovery ...
